Literature DB >> 31273432

Whole-body MRI in assessing malignant transformation in multiple hereditary exostoses and enchondromatosis: audit results and literature review.

Anne Grethe Jurik1,2, Peter Holmberg Jørgensen3, Mikkel Meng Mortensen4.   

Abstract

OBJECTIVE: To analyze the results of annual screening using whole-body magnetic resonance imaging (WBMRI) in patients with multiple hereditary exostoses (MHE) and enchondromatosis (EC), and estimate the risk for transformation to chondrosarcoma (CS) in these disorders.
MATERIALS AND METHODS: A total of 62 patients (57 with MHE and five with EC) screened during a mean follow-up period of 4.6 years (range, 1-10 years) using 253 WBMRIs (median four WBMRIs per patient, range, 1-10) were analyzed retrospectively. The time of WBMRIs was compared with dates for diagnosed CSs. A supplementary literature review was performed focusing on the risk of malignant transformation.
RESULTS: Ten patients had CS before being enrolled in the screening program, nine with MHE and one with EC. Three asymptomatic CSs were detected by screening; one in a patient with EC and two in patients with MHE, one of whom had CS previously. During the screening period, there was no occurrence of CS not detected by WBMRI in the study group. Histopathologically, the CSs were predominantly grade 1 and were, except for in two patients, located at the truncus, proximal femur, and shoulder girdle. Based on the current material and literature review, the risk of CS seems to be in the range of 2-3.7% for MHE and up to 50% for EC patients.
CONCLUSIONS: MRI may be used as a screening method detecting malignant transformation in MHE and EC patients, but the efficacy has to be confirmed in long-term follow-up studies including cost analysis.

Entities:  

Keywords:  Chondrosarcoma; Enchondromatosis; Multiple exostoses; Osteochondromatosis; Whole-body MRI

Mesh:

Year:  2019        PMID: 31273432     DOI: 10.1007/s00256-019-03268-z

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  7 in total

1.  Sarcomatous Transformation of Recurrent Scapular Osteochondroma in a Patient with the Hereditary Multiple Osteochondromas: A Case Report and Literature Review.

Authors:  Sadia Sajid; Amman Yousaf; Usman Nabi; Amir Shahbaz; Umar Amin
Journal:  Cureus       Date:  2019-12-06

Review 2.  Whole body imaging in musculoskeletal oncology: when, why, and how.

Authors:  Joao R T Vicentini; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2022-07-09       Impact factor: 2.199

3.  Diagnostic Value of CT- and MRI-Based Texture Analysis and Imaging Findings for Grading Cartilaginous Tumors in Long Bones.

Authors:  Xue-Ying Deng; Hai-Yan Chen; Jie-Ni Yu; Xiu-Liang Zhu; Jie-Yu Chen; Guo-Liang Shao; Ri-Sheng Yu
Journal:  Front Oncol       Date:  2021-10-14       Impact factor: 6.244

4.  Endoscopic endonasal extreme far-medial approach for a lower clivus osteochondroma in a patient with hereditary multiple exostoses: illustrative case.

Authors:  Yusuke Morinaga; Hiroyoshi Akutsu; Hiroyoshi Kino; Shuho Tanaka; Hidetaka Miyamoto; Masahide Matsuda; Muneyoshi Yasuda; Eiichi Ishikawa
Journal:  J Neurosurg Case Lessons       Date:  2021-05-17

5.  Premalignant Conditions of Bone.

Authors:  Michael D Eckhoff; Matthew E Wells; Osvaldo Padilla; Elizabeth M Polfer; Christopher J Castagno; Ahmed M Thabet; Shaimaa Elzamly; Harry L Wilson; Rajiv Rajani
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-10-13

Review 6.  Update on the imaging features of the enchondromatosis syndromes.

Authors:  Ban Sharif; Daniel Lindsay; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2021-07-24       Impact factor: 2.199

Review 7.  Hereditary Multiple Exostoses-A Review of the Molecular Background, Diagnostics, and Potential Therapeutic Strategies.

Authors:  Ewelina Bukowska-Olech; Wiktoria Trzebiatowska; Wiktor Czech; Olga Drzymała; Piotr Frąk; Franciszek Klarowski; Piotr Kłusek; Anna Szwajkowska; Aleksander Jamsheer
Journal:  Front Genet       Date:  2021-12-10       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.